Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER's Cost-Effectiveness Estimates.
Rachel Milstein BreslauJoshua T CohenDaniel A OllendorfPeter J NeumannPublished in: PharmacoEconomics - open (2022)